Several experimental in vitro and in vivo studies as well as clinical trials revealed that the KEAP1-Nrf2 pathway as well as its downstream mediators has been recognized as key players in the evolution of ALS. This evidence concerns the gene KEAP1 and amyotrophic lateral sclerosis.